In this online CME self-learning activity:
Schizophrenia, by nature, presents manifold challenges to the HCP directing neuropsychiatric care. Not only do practical matters like medication adherence play a role in the success of therapy, but it behooves clinicians to also have a well-informed understanding of the symptomatology and treatment course of the disease. Atypical antipsychotics are the mainstay of initial pharmacotherapy, with oral agents being preferred first. However, they have sometimes been associated with poor patient adherence, which is associated with suboptimal clinical outcomes. In contrast, improving adherence may enhance quality of life and reduce the risk of hospitalization, thereby potentially lowering health resource utilization and its associated costs.
Healthcare professionals who are: psychiatrists and primary care physicians; nurse practitioners, physician assistants, nurses, and pharmacists who specialize in psychiatry; and those who otherwise commonly care for or clinically encounter patients who have schizophrenia.
Commercial Support Disclosure: This activity is supported by an educational grant from Alkermes.
Learners may participate in this activity free of charge.
Release Date: March 06, 2020 -- Expiration Date: March 06, 2022
Faculty: Samir Sabbag, MD
Faculty introduction, disclosures |
Primer on schizophrenia’s epidemiology, neuropathophysiology, presentation, comorbidities, and psychosocial impact
|
Updates in schizophrenia treatment and strategies for barriers to care
|
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #201861248
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved through content review by ScientiaCME.
Faculty Disclosure: Samir Sabbag, MD, , has no relevant financial disclosures.
Commercial Support Disclosure: This activity is supported by an educational grant from Alkermes.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Addressing barriers to optimal care in schizophrenia with pharmacotherapy
Updates in alcohol use disorder (AUD) pharmacotherapy and barriers to optimal care
Bipolar and mood disorder: Therapeutic updates and best practices
Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care